These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 20827547

  • 1. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
    Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S, DAPS Investigators.
    Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
    [Abstract] [Full Text] [Related]

  • 2. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
    Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, DAPS Investigators.
    Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
    [Abstract] [Full Text] [Related]

  • 3. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 4. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group.
    N Engl J Med; 2006 Feb 23; 354(8):821-31. PubMed ID: 16495394
    [Abstract] [Full Text] [Related]

  • 5. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.
    Kendler DL, Macarios D, Lillestol MJ, Moffett A, Satram-Hoang S, Huang J, Kaur P, Tang ET, Wagman RB, Horne R.
    Menopause; 2014 Jan 23; 21(1):25-32. PubMed ID: 23676636
    [Abstract] [Full Text] [Related]

  • 6. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A.
    Osteoporos Int; 2014 Jan 23; 25(1):339-47. PubMed ID: 24091594
    [Abstract] [Full Text] [Related]

  • 7. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
    Gold DT, Horne R, Coon CD, Price MA, Borenstein J, Varon SF, Satram-Hoang S, Macarios D.
    Value Health; 2011 Dec 23; 14(8):1109-16. PubMed ID: 22152181
    [Abstract] [Full Text] [Related]

  • 8. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group.
    J Bone Miner Res; 2007 Dec 23; 22(12):1832-41. PubMed ID: 17708711
    [Abstract] [Full Text] [Related]

  • 9. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G, Kalouche-Khalil L, Fahrleitner-Pammer A.
    Osteoporos Int; 2015 Oct 23; 26(10):2479-89. PubMed ID: 26018090
    [Abstract] [Full Text] [Related]

  • 10. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May 23; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 11. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
    Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, Borenstein J, Wang H, Man HS, Wagman RB, Siddhanti S, Macarios D, Bone HG.
    Osteoporos Int; 2010 May 23; 21(5):837-46. PubMed ID: 19657689
    [Abstract] [Full Text] [Related]

  • 12. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
    Moen MD, Keam SJ.
    Drugs Aging; 2011 Jan 01; 28(1):63-82. PubMed ID: 21174488
    [Abstract] [Full Text] [Related]

  • 13. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.
    J Bone Miner Res; 2010 Jan 01; 25(1):72-81. PubMed ID: 19594293
    [Abstract] [Full Text] [Related]

  • 14. Bone Mineral Density After Transitioning From Denosumab to Alendronate.
    Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK.
    J Clin Endocrinol Metab; 2020 Mar 01; 105(3):e255-64. PubMed ID: 31665314
    [Abstract] [Full Text] [Related]

  • 15. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
    Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C.
    Osteoporos Int; 2015 Jan 01; 26(1):361-72. PubMed ID: 25236877
    [Abstract] [Full Text] [Related]

  • 16. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S, Agodoa I, Bonnick S, Van den Bergh JP, Ferreira I, Ho PR, Brown JP.
    J Clin Endocrinol Metab; 2015 Mar 01; 100(3):E487-92. PubMed ID: 25514106
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
    Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG.
    J Bone Miner Res; 2009 Jan 01; 24(1):153-61. PubMed ID: 18767928
    [Abstract] [Full Text] [Related]

  • 18. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients.
    Morizio P, Burkhart JI, Ozawa S.
    Ann Pharmacother; 2018 Oct 01; 52(10):1031-1041. PubMed ID: 29616561
    [Abstract] [Full Text] [Related]

  • 19. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C, Tebe C, Martinez-Laguna D, Ali MS, Soria-Castro A, Carbonell C, Prieto-Alhambra D.
    Osteoporos Int; 2017 Oct 01; 28(10):2997-3004. PubMed ID: 28714038
    [Abstract] [Full Text] [Related]

  • 20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 01; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.